VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).

VolitionRx (VNRX) stock jumped 70% in pre-market after achieving 99% pure tumor DNA isolation and detecting 49/49 cancers in a blind study.

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. HENDERSON, Nev., March 18, ...

A research team from the Guangzhou Institutes of Biomedicine and Health under the Chinese Academy of Sciences, Guangzhou Medical University and other institutions, utilized membrane vesicles from red ...

According to the study published on Wednesday in the journal Cell, the therapy proposes a brand-new strategy in the field of regenerative medicine, shedding fresh light on intervention in refractory ...

A high-fat diet can cause the intestinal lining to weaken, allowing live gut bacteria to travel directly to the brain in mice ...

This article explores how multiomics integration, imaging, and bioinformatics are advancing biomarker discovery, revealing ...

Market has emerged as a rapidly expanding segment within the oncology diagnostics and liquid biopsy landscape. Circulating ...

Invincible Season 4 returns with an explosive three-part premiere, as Mark Grayson faces intense battles and family tensions.

A silent revolution is unfolding inside Indian laboratories. From the patent-free power of an indigenous CRISPR tool to ...

Haunted by the cystic fibrosis patients he could not help, one Iowa doctor commits his life to understanding what is broken deep inside their cells.